SELLAS Life Sciences Group (NASDAQ:SLS) Stock Jumps 7.4% - Here's Why

Key Points

• SELLAS shares rose 7.4% to about $10.72 in Monday trading, with 2.66 million shares changing hands—66% below the average daily volume.
• Analyst sentiment remains mixed: Alliance Global Partners maintained a Buy rating, while Weiss Ratings reiterated Sell; MarketBeat reports a consensus Hold rating and a $10 price target.
• The clinical-stage cancer therapy company recently reported a quarterly loss of $0.05 per share, missing estimates by $0.01, while institutional investors own 17.38% of its stock.

SELLAS Life Sciences Group, Inc. (NASDAQ:SLS - Get Free Report)'s share price shot up 7.4% on Monday. The company traded as high as $10.65 and last traded at $10.7150. 2,659,286 shares changed hands during mid-day trading, a decline of 66% from the average daily volume of 7,872,056 shares. The stock had previously closed at $9.98.

Wall Street Analysts Forecast Growth

Several brokerages have commented on SLS. Weiss Ratings reissued a "sell (d-)" rating on shares of SELLAS Life Sciences Group in a research report on Thursday. Alliance Global Partners reaffirmed a "buy" rating on shares of SELLAS Life Sciences Group in a research report on Wednesday, August 12th. Two investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company's stock. Based on data from MarketBeat, SELLAS Life Sciences Group presently has a consensus rating of "Hold" and a consensus price target of $10.00.

SELLAS Life Sciences Group Stock Performance

The company has a market cap of $2.17 billion, a P/E ratio of -51.21 and a beta of 2.56. The business's 50-day moving average price is $12.46 and its 200 day moving average price is $9.93.

SELLAS Life Sciences Group (NASDAQ:SLS - Get Free Report) last issued its earnings results on Tuesday, August 11th. The company reported ($0.05) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.04) by ($0.01).

Hedge Funds Weigh In On SELLAS Life Sciences Group

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Nykredit A S bought a new position in SELLAS Life Sciences Group in the 2nd quarter valued at about $27,000. GAMMA Investing LLC boosted its holdings in shares of SELLAS Life Sciences Group by 293.2% during the third quarter. GAMMA Investing LLC now owns 2,186 shares of the company's stock worth $27,000 after acquiring an additional 1,630 shares during the period. California State Teachers Retirement System grew its position in shares of SELLAS Life Sciences Group by 22.4% in the first quarter. California State Teachers Retirement System now owns 9,337 shares of the company's stock valued at $39,000 after purchasing an additional 1,709 shares during the last quarter. Wealthfront Advisers LLC acquired a new position in shares of SELLAS Life Sciences Group in the first quarter valued at approximately $48,000. Finally, Principal Financial Group Inc. bought a new position in shares of SELLAS Life Sciences Group during the first quarter worth approximately $53,000. 17.38% of the stock is owned by institutional investors.

SELLAS Life Sciences Group Company Profile

SELLAS Life Sciences Group, Inc is a clinical-stage biopharmaceutical company focused on developing novel cancer therapies, particularly immunotherapies and targeted treatments for patients with difficult-to-treat malignancies. The company's research and development programs are designed to address cancers with significant unmet medical needs.

SELLAS's lead immunotherapy candidate, galinpepimut-S (GPS), is a multi-peptide vaccine intended to stimulate the immune system against Wilms' tumor 1 (WT1), a protein expressed in several types of cancer.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.